A novel bisindolymaleimide derivative (WK234) inhibits proliferation and induces apoptosis through the protein kinase Cβ pathway, in chronic myelogenous leukemia K562 cells

References

• Mackay HJ, Twelves CJ. Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 2007;7:554–562.
   PubMed Web of Science ®Google Scholar
• Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007;7:281–294.
   PubMed Web of Science ®Google Scholar
• Coussens L, Rhee L, Parker PJ, Ullrich A. Alternative splicing increases the diversity of the human protein kinase C family. DNA 1987;6:389–394.
   PubMedGoogle Scholar
• Kubo K, Ohno S, Suzuki K. Primary structures of human protein kinase C beta I and beta II differ only in their C-terminal sequences. FEBS Lett 1987;223:138–142.
   PubMed Web of Science ®Google Scholar
• Li H, Weinstein IB. Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells. Cancer Res 2006;66:11399–11408.
   PubMed Web of Science ®Google Scholar
• Guo K, Liu Y, Zhou H, et al. Involvement of protein kinase C beta-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion. Cancer Sci 2008;99:486–496.
   PubMed Web of Science ®Google Scholar
• Lahn M, McClelland P, Ballard D, Mintze K, Thornton D, Sandusky G. Immunohistochemical detection of protein kinase C-beta (PKC-beta) in tumour specimens of patients with non-small cell lung cancer. Histopathology 2006;49:429–431.
   PubMed Web of Science ®Google Scholar
• Gokmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP. Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res 2001;61:1375–1381.
   PubMed Web of Science ®Google Scholar
• Murray NR, Davidson LA, Chapkin RS, Clay Gustafson W, Schattenberg DG, Fields AP. Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 1999;145:699–711.
   PubMedGoogle Scholar
• Kim J, Choi YL, Vallentin A, et al. Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res 2008;68:6831–6839.
   Google Scholar
• Holler C, Pinon JD, Denk U, et al. PKCbeta is essential for the development of CLL in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in CLL. Blood 2009;13:2791–2794.
   Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68–74.
   PubMed Web of Science ®Google Scholar
• Li S, Phong M, Lahn M, et al. Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas. Biol Direct 2007;2:8.
   PubMed Web of Science ®Google Scholar
• Schaffel R, Morais JC, Biasoli I, et al. PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma. Mod Pathol 2007;20:326–330.
   PubMed Web of Science ®Google Scholar
• Murray NR, Burns DJ, Fields AP. Presence of a beta II protein kinase C-selective nuclear membrane activation factor in human leukemia cells. J Biol Chem 1994;269:21385–21390.
   PubMed Web of Science ®Google Scholar
• Murray NR, Baumgardner GP, Burns DJ, Fields AP. Protein kinase C isotypes in human erythroleukemia (K562) cell proliferation and differentiation. Evidence that beta II protein kinase C is required for proliferation. J Biol Chem 1993;268:15847–15853.
   PubMed Web of Science ®Google Scholar
• Wang K, Li XY, Chen XG, Liu ZZ. Synthesis and antitumor activity of bisindolylmaleimide and amino acid ester conjugates. J Asian Nat Prod Res 2010;12:36–42.
   PubMed Web of Science ®Google Scholar
• Podar K, Tai YT, Lin BK, et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem 2002;277:7875–7881.
   PubMed Web of Science ®Google Scholar
• Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007;109:1669–1677.
   PubMed Web of Science ®Google Scholar
• Rieger J, Lemke D, Maurer G, et al. Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. J Neurochem 2008;106:2436–2448.
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462–469.
   PubMed Web of Science ®Google Scholar
• Lee KW, Kim SG, Kim HP, et al. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 2008;68:1916–1926.
   PubMed Web of Science ®Google Scholar
• Rizvi MA, Ghias K, Davies KM, et al. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006;5:1783–1789.
   PubMed Web of Science ®Google Scholar
• Verdelli D, Nobili L, Todoerti K, et al. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. Hematol Oncol 2009;27:23–30.
   PubMed Web of Science ®Google Scholar
• Neri A, Marmiroli S, Tassone P, et al. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma 2008;49:1374–1383.
   PubMed Web of Science ®Google Scholar
• Civallero M, Cosenza M, Grisendi G, Marcheselli L, Todoerti K, Sacchi S. Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. Leuk Lymphoma 2010;51:671–679.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006;126:1641–1647.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005;18:1377–1384.
   PubMed Web of Science ®Google Scholar
• Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770–776.
   PubMed Web of Science ®Google Scholar
• Keranen LM, Dutil EM, Newton AC. Protein kinase C is regulated in vivo by three functionally distinct phosphorylations. Curr Biol 1995;5:1394–1403.
   PubMed Web of Science ®Google Scholar
• Newton AC. Protein kinase C: structure, function, and regulation. J Biol Chem 1995;270:28495–28498.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang L, Schwartz J, Bond RW, Bishop WR. Phosphorylation of Thr642 is an early event in the processing of newly synthesized protein kinase C beta 1 and is essential for its activation. J Biol Chem 1994;269:19578–19584.
   PubMed Web of Science ®Google Scholar
• Newton AC. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 2001;101:2353–2364.
   PubMed Web of Science ®Google Scholar
• Newton AC, Johnson JE. Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Biochim Biophys Acta 1998;1376:155–172.
   PubMed Web of Science ®Google Scholar
• Goode N, Hughes K, Woodgett JR, Parker PJ. Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. J Biol Chem 1992;267:16878–16882.
   PubMed Web of Science ®Google Scholar